Clinical trial · Observational
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. Secondary objectives: To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteoporosis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis.
- timeFrame
- 6 months
Secondary outcomes (3)
- measure
- To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists.
- timeFrame
- 6 months
- measure
- To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics
- timeFrame
- 6 months
- measure
- To evaluate incidence of osteopenia/osteoporosis in this study population.
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Man with Prostate Cancer * Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis * Osteopenia/osteoporosis proven by bone density test. Exclusion Criteria: * Creatinine clearance \< 30ml/min * Hypercalcemia * Actual treatment by Bisphosphonate or steroids * Hypersensibility to Bisphosphonate or any contraindication to its use. * Metastatic prostate Cancer * Patients not suitable for compliance. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available